BMO Capital analyst Michael Zaremski downgraded Ryan Specialty (RYAN) to Market Perform from Outperform with a price target of $43, down from $66. The firm believes the excess and surplus marketplace, where Ryan predominantly competes, will continue to experience “material growth deceleration” through 2027. The firm reduced the company’s estimates to reflect lower organic growth, worse margins, and less acquisition revenue.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYAN:
- The Week That Was, The Week Ahead: Macro and Markets, Feb. 22
- Ryan Specialty price target lowered to $65 from $71 at UBS
- Ryan Specialty price target lowered to $45 from $52 at Cantor Fitzgerald
- Ryan Specialty Earnings Call: Growth Strong, Margins Pinched
- Ryan Specialty: Long-Term Earnings Power and Delegated Authority Strategy Justify Buy Rating Despite Near-Term Softness